Breast diseaseHumansFemaleRetrospective StudiesBreast NeoplasmsNeoadjuvant Therapy
Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapy.
Meiko Nishimura, Takayuki Kobayashi, Yosuke Aoyama, Saori Kawai, Jun Masuda, Yukinori Ozaki, Mari Hosonaga, Ippei Fukada, Tetsuyo Maeda, Nami Yamashita, Tomo Osako, Toshimi Takano, Takayuki Ueno
Published: 202510.1177/15581551251403784
Abstract
BackgroundTrastuzumab emtansine (T-DM1) is indicated for HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy (NAC). However, the extent of benefit T-DM1 will provide over trastuzumab plus pertuzumab (HP) in…
Preview only. Read the full abstract at the source